Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-FAST blood-first targeted therapy trial in advanced or metastatic NSCLC
2017-000076-28Phase 2Active
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib and atezolizumab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Roche. Primary endpoint: Objective response rate. Started May 2017; status: active.
02
Drugs
alectinibatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-000076-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000076-28.